Catabasis Pharmaceuticals, Inc. (CATB)
(Delayed Data from NSDQ)
$7.77 USD
+0.22 (2.91%)
Updated May 3, 2019 04:00 PM ET
After-Market: $7.75 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Astria Therapeutics, Inc. [CATB]
Reports for Purchase
Showing records 1 - 20 ( 155 total )
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initiating at Outperform, $16 Target; Hit Me With Your Best Shot
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
QLS-215 Differentiated Profile and Upcoming Catalysts Get Us Back in Game
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Results; All Eyes On QLS-215 as Differentiated Program Marches Toward IND
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Results; QLS-215 On Track To Tackle HAE in 1H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2020 Results; Stage Set for New Future with QLS-215
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Dropping Coverage Due to Realignment of Analyst Resources
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Downgrading to NEUTRAL; Edasalonexent/DMD Discontinued
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Edasalonexent Fails to Meet Endpoints in DMD; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Beating Inflammation for Improved Mobility in DMD; Imminent Pivotal Data; Initiating at Buy and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KOL Enthusiastic About Edasalonexent; Next, Topline Ph3 PolarisDMD Data in Q4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Sights Set on Topline Pivotal Phase 3 PolarisDMD Data in Q4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L